Remlarsen - Viridian Therapeutics
Alternative Names: miR-29 replacement; MRG-201Latest Information Update: 02 Jul 2024
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Viridian Therapeutics; Yale University
- Class Antifibrotics; Eye disorder therapies; Skin disorder therapies
- Mechanism of Action Collagen expression inhibitors; Protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Eye disorders; Fibrosis; Pulmonary fibrosis
Most Recent Events
- 02 Jul 2024 Discontinued - Phase-I for Fibrosis (In volunteers) in Canada (Intradermal) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
- 02 Jul 2024 Discontinued - Phase-II for Fibrosis (In the elderly, In adults) in USA (Intradermal) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
- 02 Jul 2024 Discontinued - Preclinical for Eye disorders in USA (Intravitreous) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)